Evidence Hub

Efficacy of Intravenous Tenecteplase Bridge Thrombectomy for Recurrent Ischemic Stroke Within 3 Months: A Case Report

Cuicui Liu, Junyan Liu, Huiling Ren, Yuzhu Xu, Wan-Hu Liu

International Medical Case Reports Journal, 2025

1 citation

Abstract

Abstract In the previous guideline recommendations, patients who have had a stroke within 3 months are excluded from intravenous thrombolysis (IVT) regimens. Some studies have suggested that IVT with alteplase (rt-PA) may be effective and safe in such patients, but evidence supporting the use of tenecteplase (TNK) is not sufficient. This paper includes an 80-year-old male patient readmitted for recurrence of ischaemic stroke (IS) after 48 days, who received TNK IVT as a bridging therapy prior to thrombectomy, with favourable results at 8-week follow-up. This case highlights that TNK alone or IVT as a bridging therapy prior to thrombectomy can also benefit patients with recurrent stroke within 3 months.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free